nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—connective tissue—systemic scleroderma	0.0173	0.417	CbGeAlD
Maraviroc—CCR5—digestive system—systemic scleroderma	0.0125	0.301	CbGeAlD
Maraviroc—CCR5—lung—systemic scleroderma	0.0104	0.252	CbGeAlD
Maraviroc—CCR5—IL12-mediated signaling events—CD247—systemic scleroderma	0.00324	0.146	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT4—systemic scleroderma	0.00285	0.129	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD247—systemic scleroderma	0.00234	0.106	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL2—systemic scleroderma	0.0014	0.063	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL1A—systemic scleroderma	0.00139	0.0627	CbGpPWpGaD
Maraviroc—CYP3A4—digestive system—systemic scleroderma	0.00126	0.0304	CbGeAlD
Maraviroc—CCR5—HIV Infection—CD247—systemic scleroderma	0.00116	0.0525	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL1B—systemic scleroderma	0.001	0.0452	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000769	0.0347	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000725	0.0327	CbGpPWpGaD
Maraviroc—Loss of consciousness—Lisinopril—systemic scleroderma	0.000584	0.000624	CcSEcCtD
Maraviroc—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000582	0.000622	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000581	0.00062	CcSEcCtD
Maraviroc—Cough—Lisinopril—systemic scleroderma	0.00058	0.00062	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000578	0.000618	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000577	0.000616	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000575	0.000614	CcSEcCtD
Maraviroc—Anorexia—Mycophenolic acid—systemic scleroderma	0.000574	0.000613	CcSEcCtD
Maraviroc—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000574	0.000613	CcSEcCtD
Maraviroc—Insomnia—Leflunomide—systemic scleroderma	0.000571	0.00061	CcSEcCtD
Maraviroc—Abdominal distension—Prednisone—systemic scleroderma	0.00057	0.000609	CcSEcCtD
Maraviroc—Paraesthesia—Leflunomide—systemic scleroderma	0.000567	0.000606	CcSEcCtD
Maraviroc—Myalgia—Lisinopril—systemic scleroderma	0.000566	0.000604	CcSEcCtD
Maraviroc—Anxiety—Lisinopril—systemic scleroderma	0.000564	0.000602	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000563	0.0254	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000562	0.0006	CcSEcCtD
Maraviroc—Discomfort—Lisinopril—systemic scleroderma	0.000559	0.000597	CcSEcCtD
Maraviroc—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000559	0.000597	CcSEcCtD
Maraviroc—Pancreatitis—Prednisone—systemic scleroderma	0.000556	0.000593	CcSEcCtD
Maraviroc—Vomiting—Mometasone—systemic scleroderma	0.000555	0.000592	CcSEcCtD
Maraviroc—Rash—Mometasone—systemic scleroderma	0.00055	0.000587	CcSEcCtD
Maraviroc—Asthenia—Captopril—systemic scleroderma	0.00055	0.000587	CcSEcCtD
Maraviroc—Dermatitis—Mometasone—systemic scleroderma	0.000549	0.000587	CcSEcCtD
Maraviroc—Decreased appetite—Leflunomide—systemic scleroderma	0.000549	0.000586	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000549	0.000586	CcSEcCtD
Maraviroc—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000547	0.000584	CcSEcCtD
Maraviroc—Headache—Mometasone—systemic scleroderma	0.000546	0.000584	CcSEcCtD
Maraviroc—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000546	0.000583	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000545	0.000582	CcSEcCtD
Maraviroc—Insomnia—Mycophenolic acid—systemic scleroderma	0.000545	0.000582	CcSEcCtD
Maraviroc—Fatigue—Leflunomide—systemic scleroderma	0.000544	0.000581	CcSEcCtD
Maraviroc—Oedema—Lisinopril—systemic scleroderma	0.000543	0.000579	CcSEcCtD
Maraviroc—Pruritus—Captopril—systemic scleroderma	0.000542	0.000579	CcSEcCtD
Maraviroc—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000541	0.000578	CcSEcCtD
Maraviroc—Constipation—Leflunomide—systemic scleroderma	0.00054	0.000577	CcSEcCtD
Maraviroc—Pain—Leflunomide—systemic scleroderma	0.00054	0.000577	CcSEcCtD
Maraviroc—Infection—Lisinopril—systemic scleroderma	0.000539	0.000576	CcSEcCtD
Maraviroc—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000575	CcSEcCtD
Maraviroc—Shock—Lisinopril—systemic scleroderma	0.000534	0.00057	CcSEcCtD
Maraviroc—Neutropenia—Prednisone—systemic scleroderma	0.00053	0.000566	CcSEcCtD
Maraviroc—Abdominal pain—Azathioprine—systemic scleroderma	0.000529	0.000564	CcSEcCtD
Maraviroc—Body temperature increased—Azathioprine—systemic scleroderma	0.000529	0.000564	CcSEcCtD
Maraviroc—Skin disorder—Lisinopril—systemic scleroderma	0.000527	0.000563	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000525	0.0237	CbGpPWpGaD
Maraviroc—Diarrhoea—Captopril—systemic scleroderma	0.000524	0.00056	CcSEcCtD
Maraviroc—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000524	0.000559	CcSEcCtD
Maraviroc—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000522	0.000558	CcSEcCtD
Maraviroc—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000521	0.000557	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00052	0.000555	CcSEcCtD
Maraviroc—Fatigue—Mycophenolic acid—systemic scleroderma	0.000519	0.000555	CcSEcCtD
Maraviroc—Nausea—Mometasone—systemic scleroderma	0.000518	0.000553	CcSEcCtD
Maraviroc—Anorexia—Lisinopril—systemic scleroderma	0.000517	0.000552	CcSEcCtD
Maraviroc—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000516	0.000551	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000516	0.0233	CbGpPWpGaD
Maraviroc—Constipation—Mycophenolic acid—systemic scleroderma	0.000515	0.00055	CcSEcCtD
Maraviroc—Pain—Mycophenolic acid—systemic scleroderma	0.000515	0.00055	CcSEcCtD
Maraviroc—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000512	0.000547	CcSEcCtD
Maraviroc—Cough—Mycophenolate mofetil—systemic scleroderma	0.000508	0.000543	CcSEcCtD
Maraviroc—Dizziness—Captopril—systemic scleroderma	0.000507	0.000541	CcSEcCtD
Maraviroc—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000505	0.000539	CcSEcCtD
Maraviroc—Depression—Prednisone—systemic scleroderma	0.000504	0.000538	CcSEcCtD
Maraviroc—Abdominal pain—Leflunomide—systemic scleroderma	0.000499	0.000533	CcSEcCtD
Maraviroc—Body temperature increased—Leflunomide—systemic scleroderma	0.000499	0.000533	CcSEcCtD
Maraviroc—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000498	0.000532	CcSEcCtD
Maraviroc—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000496	0.00053	CcSEcCtD
Maraviroc—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000495	0.000529	CcSEcCtD
Maraviroc—Myocardial infarction—Prednisone—systemic scleroderma	0.000495	0.000529	CcSEcCtD
Maraviroc—Breast disorder—Methotrexate—systemic scleroderma	0.000495	0.000529	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000494	0.000528	CcSEcCtD
Maraviroc—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000494	0.000528	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000493	0.000527	CcSEcCtD
Maraviroc—Hypersensitivity—Azathioprine—systemic scleroderma	0.000493	0.000526	CcSEcCtD
Maraviroc—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000493	0.000526	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000492	0.000526	CcSEcCtD
Maraviroc—Insomnia—Lisinopril—systemic scleroderma	0.000491	0.000524	CcSEcCtD
Maraviroc—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00049	0.000523	CcSEcCtD
Maraviroc—Paraesthesia—Lisinopril—systemic scleroderma	0.000487	0.00052	CcSEcCtD
Maraviroc—Vomiting—Captopril—systemic scleroderma	0.000487	0.00052	CcSEcCtD
Maraviroc—Rash—Captopril—systemic scleroderma	0.000483	0.000516	CcSEcCtD
Maraviroc—Dermatitis—Captopril—systemic scleroderma	0.000483	0.000515	CcSEcCtD
Maraviroc—Headache—Captopril—systemic scleroderma	0.00048	0.000513	CcSEcCtD
Maraviroc—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000476	0.000509	CcSEcCtD
Maraviroc—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000476	0.000509	CcSEcCtD
Maraviroc—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000475	0.000508	CcSEcCtD
Maraviroc—Infection—Mycophenolate mofetil—systemic scleroderma	0.000472	0.000504	CcSEcCtD
Maraviroc—Decreased appetite—Lisinopril—systemic scleroderma	0.000472	0.000504	CcSEcCtD
Maraviroc—Eosinophilia—Methotrexate—systemic scleroderma	0.000469	0.000501	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000468	0.0005	CcSEcCtD
Maraviroc—Fatigue—Lisinopril—systemic scleroderma	0.000468	0.0005	CcSEcCtD
Maraviroc—Shock—Mycophenolate mofetil—systemic scleroderma	0.000468	0.000499	CcSEcCtD
Maraviroc—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000466	0.000498	CcSEcCtD
Maraviroc—Hypersensitivity—Leflunomide—systemic scleroderma	0.000465	0.000497	CcSEcCtD
Maraviroc—Pancreatitis—Methotrexate—systemic scleroderma	0.000464	0.000496	CcSEcCtD
Maraviroc—Pain—Lisinopril—systemic scleroderma	0.000464	0.000496	CcSEcCtD
Maraviroc—Constipation—Lisinopril—systemic scleroderma	0.000464	0.000496	CcSEcCtD
Maraviroc—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000462	0.000493	CcSEcCtD
Maraviroc—Diarrhoea—Azathioprine—systemic scleroderma	0.000457	0.000489	CcSEcCtD
Maraviroc—Nausea—Captopril—systemic scleroderma	0.000455	0.000486	CcSEcCtD
Maraviroc—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000453	0.000484	CcSEcCtD
Maraviroc—Asthenia—Leflunomide—systemic scleroderma	0.000453	0.000484	CcSEcCtD
Maraviroc—Hallucination—Prednisone—systemic scleroderma	0.000451	0.000482	CcSEcCtD
Maraviroc—Pancytopenia—Methotrexate—systemic scleroderma	0.00045	0.00048	CcSEcCtD
Maraviroc—Pruritus—Leflunomide—systemic scleroderma	0.000447	0.000477	CcSEcCtD
Maraviroc—Connective tissue disorder—Prednisone—systemic scleroderma	0.000446	0.000476	CcSEcCtD
Maraviroc—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000444	0.000474	CcSEcCtD
Maraviroc—Neutropenia—Methotrexate—systemic scleroderma	0.000443	0.000473	CcSEcCtD
Maraviroc—Dizziness—Azathioprine—systemic scleroderma	0.000442	0.000472	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00044	0.00047	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—RHOB—systemic scleroderma	0.000435	0.0196	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000433	0.000463	CcSEcCtD
Maraviroc—Asthenia—Mycophenolic acid—systemic scleroderma	0.000432	0.000462	CcSEcCtD
Maraviroc—Diarrhoea—Leflunomide—systemic scleroderma	0.000432	0.000461	CcSEcCtD
Maraviroc—CCR5—Disease—SMAD7—systemic scleroderma	0.00043	0.0194	CbGpPWpGaD
Maraviroc—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00043	0.000459	CcSEcCtD
Maraviroc—Abdominal pain—Lisinopril—systemic scleroderma	0.000429	0.000458	CcSEcCtD
Maraviroc—Body temperature increased—Lisinopril—systemic scleroderma	0.000429	0.000458	CcSEcCtD
Maraviroc—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000427	0.000456	CcSEcCtD
Maraviroc—Pruritus—Mycophenolic acid—systemic scleroderma	0.000426	0.000455	CcSEcCtD
Maraviroc—Vomiting—Azathioprine—systemic scleroderma	0.000425	0.000454	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—systemic scleroderma	0.000425	0.000454	CcSEcCtD
Maraviroc—Eye disorder—Prednisone—systemic scleroderma	0.000424	0.000453	CcSEcCtD
Maraviroc—Infestation—Methotrexate—systemic scleroderma	0.000422	0.000451	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—systemic scleroderma	0.000422	0.000451	CcSEcCtD
Maraviroc—Rash—Azathioprine—systemic scleroderma	0.000422	0.00045	CcSEcCtD
Maraviroc—Dermatitis—Azathioprine—systemic scleroderma	0.000421	0.00045	CcSEcCtD
Maraviroc—Depression—Methotrexate—systemic scleroderma	0.000421	0.00045	CcSEcCtD
Maraviroc—Headache—Azathioprine—systemic scleroderma	0.000419	0.000447	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000419	0.000447	CcSEcCtD
Maraviroc—Dizziness—Leflunomide—systemic scleroderma	0.000418	0.000446	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—systemic scleroderma	0.000415	0.000443	CcSEcCtD
Maraviroc—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000413	0.000441	CcSEcCtD
Maraviroc—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000412	0.00044	CcSEcCtD
Maraviroc—Stomatitis—Methotrexate—systemic scleroderma	0.000412	0.00044	CcSEcCtD
Maraviroc—Angiopathy—Prednisone—systemic scleroderma	0.000411	0.000439	CcSEcCtD
Maraviroc—Conjunctivitis—Methotrexate—systemic scleroderma	0.00041	0.000438	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00041	0.000438	CcSEcCtD
Maraviroc—Pain—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000434	CcSEcCtD
Maraviroc—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000434	CcSEcCtD
Maraviroc—Vomiting—Leflunomide—systemic scleroderma	0.000401	0.000429	CcSEcCtD
Maraviroc—Alopecia—Prednisone—systemic scleroderma	0.000401	0.000428	CcSEcCtD
Maraviroc—Hypersensitivity—Lisinopril—systemic scleroderma	0.0004	0.000427	CcSEcCtD
Maraviroc—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000399	0.000426	CcSEcCtD
Maraviroc—Dizziness—Mycophenolic acid—systemic scleroderma	0.000398	0.000425	CcSEcCtD
Maraviroc—Rash—Leflunomide—systemic scleroderma	0.000398	0.000425	CcSEcCtD
Maraviroc—Dermatitis—Leflunomide—systemic scleroderma	0.000398	0.000425	CcSEcCtD
Maraviroc—Mental disorder—Prednisone—systemic scleroderma	0.000397	0.000424	CcSEcCtD
Maraviroc—Nausea—Azathioprine—systemic scleroderma	0.000397	0.000424	CcSEcCtD
Maraviroc—Headache—Leflunomide—systemic scleroderma	0.000396	0.000422	CcSEcCtD
Maraviroc—Erythema—Prednisone—systemic scleroderma	0.000395	0.000422	CcSEcCtD
Maraviroc—Malnutrition—Prednisone—systemic scleroderma	0.000395	0.000422	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—RHOB—systemic scleroderma	0.000395	0.0178	CbGpPWpGaD
Maraviroc—Agranulocytosis—Methotrexate—systemic scleroderma	0.000394	0.000421	CcSEcCtD
Maraviroc—CCR5—Disease—TGFBI—systemic scleroderma	0.000394	0.0178	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—EDN1—systemic scleroderma	0.000393	0.0177	CbGpPWpGaD
Maraviroc—Asthenia—Lisinopril—systemic scleroderma	0.000389	0.000416	CcSEcCtD
Maraviroc—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000389	0.000415	CcSEcCtD
Maraviroc—Pruritus—Lisinopril—systemic scleroderma	0.000384	0.00041	CcSEcCtD
Maraviroc—Vomiting—Mycophenolic acid—systemic scleroderma	0.000383	0.000409	CcSEcCtD
Maraviroc—Rash—Mycophenolic acid—systemic scleroderma	0.00038	0.000406	CcSEcCtD
Maraviroc—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000379	0.000405	CcSEcCtD
Maraviroc—Headache—Mycophenolic acid—systemic scleroderma	0.000377	0.000403	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—systemic scleroderma	0.000376	0.000402	CcSEcCtD
Maraviroc—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000401	CcSEcCtD
Maraviroc—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000401	CcSEcCtD
Maraviroc—Nausea—Leflunomide—systemic scleroderma	0.000375	0.000401	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000374	0.0004	CcSEcCtD
Maraviroc—Urethral disorder—Methotrexate—systemic scleroderma	0.000372	0.000397	CcSEcCtD
Maraviroc—Diarrhoea—Lisinopril—systemic scleroderma	0.000371	0.000396	CcSEcCtD
Maraviroc—Anaemia—Prednisone—systemic scleroderma	0.000365	0.00039	CcSEcCtD
Maraviroc—Dizziness—Lisinopril—systemic scleroderma	0.000359	0.000383	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—systemic scleroderma	0.000358	0.000383	CcSEcCtD
Maraviroc—Nausea—Mycophenolic acid—systemic scleroderma	0.000358	0.000382	CcSEcCtD
Maraviroc—Eye disorder—Methotrexate—systemic scleroderma	0.000354	0.000378	CcSEcCtD
Maraviroc—Syncope—Prednisone—systemic scleroderma	0.000354	0.000378	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000352	0.0159	CbGpPWpGaD
Maraviroc—Cardiac disorder—Methotrexate—systemic scleroderma	0.000352	0.000376	CcSEcCtD
Maraviroc—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00035	0.000374	CcSEcCtD
Maraviroc—Loss of consciousness—Prednisone—systemic scleroderma	0.000347	0.000371	CcSEcCtD
Maraviroc—Vomiting—Lisinopril—systemic scleroderma	0.000345	0.000368	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—systemic scleroderma	0.000344	0.000367	CcSEcCtD
Maraviroc—Rash—Lisinopril—systemic scleroderma	0.000342	0.000365	CcSEcCtD
Maraviroc—Convulsion—Prednisone—systemic scleroderma	0.000342	0.000365	CcSEcCtD
Maraviroc—Dermatitis—Lisinopril—systemic scleroderma	0.000342	0.000365	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000342	0.000365	CcSEcCtD
Maraviroc—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000341	0.000364	CcSEcCtD
Maraviroc—Headache—Lisinopril—systemic scleroderma	0.00034	0.000363	CcSEcCtD
Maraviroc—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000359	CcSEcCtD
Maraviroc—Myalgia—Prednisone—systemic scleroderma	0.000336	0.000359	CcSEcCtD
Maraviroc—Anxiety—Prednisone—systemic scleroderma	0.000335	0.000358	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—systemic scleroderma	0.000335	0.000358	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000334	0.000357	CcSEcCtD
Maraviroc—Discomfort—Prednisone—systemic scleroderma	0.000332	0.000355	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—systemic scleroderma	0.000332	0.000355	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—systemic scleroderma	0.00033	0.000352	CcSEcCtD
Maraviroc—Erythema—Methotrexate—systemic scleroderma	0.00033	0.000352	CcSEcCtD
Maraviroc—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000347	CcSEcCtD
Maraviroc—Nausea—Lisinopril—systemic scleroderma	0.000322	0.000344	CcSEcCtD
Maraviroc—Oedema—Prednisone—systemic scleroderma	0.000322	0.000344	CcSEcCtD
Maraviroc—Infection—Prednisone—systemic scleroderma	0.00032	0.000342	CcSEcCtD
Maraviroc—Shock—Prednisone—systemic scleroderma	0.000317	0.000339	CcSEcCtD
Maraviroc—Nervous system disorder—Prednisone—systemic scleroderma	0.000316	0.000337	CcSEcCtD
Maraviroc—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000314	0.000336	CcSEcCtD
Maraviroc—CCR5—Disease—HSPG2—systemic scleroderma	0.000314	0.0142	CbGpPWpGaD
Maraviroc—Skin disorder—Prednisone—systemic scleroderma	0.000313	0.000334	CcSEcCtD
Maraviroc—Anorexia—Prednisone—systemic scleroderma	0.000307	0.000328	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—systemic scleroderma	0.000305	0.000326	CcSEcCtD
Maraviroc—CCR5—Disease—CSK—systemic scleroderma	0.000303	0.0137	CbGpPWpGaD
Maraviroc—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000302	0.000323	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SMAD7—systemic scleroderma	0.000301	0.0136	CbGpPWpGaD
Maraviroc—Rash—Mycophenolate mofetil—systemic scleroderma	0.0003	0.00032	CcSEcCtD
Maraviroc—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000299	0.00032	CcSEcCtD
Maraviroc—Headache—Mycophenolate mofetil—systemic scleroderma	0.000298	0.000318	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—systemic scleroderma	0.000295	0.000315	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000294	0.000314	CcSEcCtD
Maraviroc—Insomnia—Prednisone—systemic scleroderma	0.000291	0.000311	CcSEcCtD
Maraviroc—Paraesthesia—Prednisone—systemic scleroderma	0.000289	0.000309	CcSEcCtD
Maraviroc—Cough—Methotrexate—systemic scleroderma	0.000288	0.000308	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—systemic scleroderma	0.000286	0.000305	CcSEcCtD
Maraviroc—CCR5—Disease—CD247—systemic scleroderma	0.000285	0.0129	CbGpPWpGaD
Maraviroc—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000282	0.000302	CcSEcCtD
Maraviroc—Myalgia—Methotrexate—systemic scleroderma	0.000281	0.0003	CcSEcCtD
Maraviroc—Decreased appetite—Prednisone—systemic scleroderma	0.00028	0.000299	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000279	0.000298	CcSEcCtD
Maraviroc—Fatigue—Prednisone—systemic scleroderma	0.000278	0.000297	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—systemic scleroderma	0.000278	0.000296	CcSEcCtD
Maraviroc—Constipation—Prednisone—systemic scleroderma	0.000276	0.000294	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CCL2—systemic scleroderma	0.000268	0.0121	CbGpPWpGaD
Maraviroc—Infection—Methotrexate—systemic scleroderma	0.000268	0.000286	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—systemic scleroderma	0.000264	0.000282	CcSEcCtD
Maraviroc—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000263	0.000281	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—systemic scleroderma	0.000262	0.000279	CcSEcCtD
Maraviroc—Anorexia—Methotrexate—systemic scleroderma	0.000257	0.000274	CcSEcCtD
Maraviroc—Abdominal pain—Prednisone—systemic scleroderma	0.000255	0.000272	CcSEcCtD
Maraviroc—Body temperature increased—Prednisone—systemic scleroderma	0.000255	0.000272	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000245	0.000262	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—systemic scleroderma	0.000244	0.00026	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—systemic scleroderma	0.000242	0.000258	CcSEcCtD
Maraviroc—Hypersensitivity—Prednisone—systemic scleroderma	0.000237	0.000254	CcSEcCtD
Maraviroc—Decreased appetite—Methotrexate—systemic scleroderma	0.000234	0.00025	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RHOB—systemic scleroderma	0.000233	0.0105	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000232	0.000248	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—systemic scleroderma	0.000232	0.000248	CcSEcCtD
Maraviroc—Asthenia—Prednisone—systemic scleroderma	0.000231	0.000247	CcSEcCtD
Maraviroc—Pain—Methotrexate—systemic scleroderma	0.00023	0.000246	CcSEcCtD
Maraviroc—Pruritus—Prednisone—systemic scleroderma	0.000228	0.000243	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—EDN1—systemic scleroderma	0.000222	0.01	CbGpPWpGaD
Maraviroc—Diarrhoea—Prednisone—systemic scleroderma	0.00022	0.000235	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00022	0.000235	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HSPG2—systemic scleroderma	0.00022	0.00991	CbGpPWpGaD
Maraviroc—Dizziness—Prednisone—systemic scleroderma	0.000213	0.000228	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—systemic scleroderma	0.000213	0.000227	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—systemic scleroderma	0.000213	0.000227	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CSK—systemic scleroderma	0.000212	0.00958	CbGpPWpGaD
Maraviroc—Vomiting—Prednisone—systemic scleroderma	0.000205	0.000219	CcSEcCtD
Maraviroc—Rash—Prednisone—systemic scleroderma	0.000203	0.000217	CcSEcCtD
Maraviroc—Dermatitis—Prednisone—systemic scleroderma	0.000203	0.000217	CcSEcCtD
Maraviroc—Headache—Prednisone—systemic scleroderma	0.000202	0.000216	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EDN1—systemic scleroderma	0.000201	0.00909	CbGpPWpGaD
Maraviroc—Hypersensitivity—Methotrexate—systemic scleroderma	0.000198	0.000212	CcSEcCtD
Maraviroc—Asthenia—Methotrexate—systemic scleroderma	0.000193	0.000206	CcSEcCtD
Maraviroc—Nausea—Prednisone—systemic scleroderma	0.000191	0.000204	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—systemic scleroderma	0.000191	0.000203	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—systemic scleroderma	0.000184	0.000197	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—systemic scleroderma	0.000178	0.00019	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—systemic scleroderma	0.000171	0.000183	CcSEcCtD
Maraviroc—Rash—Methotrexate—systemic scleroderma	0.00017	0.000181	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—systemic scleroderma	0.00017	0.000181	CcSEcCtD
Maraviroc—Headache—Methotrexate—systemic scleroderma	0.000169	0.00018	CcSEcCtD
Maraviroc—Nausea—Methotrexate—systemic scleroderma	0.00016	0.000171	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCL2—systemic scleroderma	0.000138	0.00621	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDN1—systemic scleroderma	0.000119	0.00537	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS3—systemic scleroderma	0.000104	0.00467	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL2—systemic scleroderma	8.14e-05	0.00367	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOS3—systemic scleroderma	7.25e-05	0.00327	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—systemic scleroderma	6.85e-05	0.00309	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—systemic scleroderma	5.82e-05	0.00262	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—systemic scleroderma	4.8e-05	0.00216	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.96e-05	0.000884	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.49e-05	0.00067	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.46e-06	0.000292	CbGpPWpGaD
